Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring over 8% in pre-market trading on Wednesday.
The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system. The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.
Dr. Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, expressed excitement about the integration, stating that it "removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care." The integration aligns with SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for partners.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。